SG Americas Securities LLC Raises Stock Holdings in Genelux Co. (NASDAQ:GNLX)

SG Americas Securities LLC lifted its holdings in shares of Genelux Co. (NASDAQ:GNLX) by 45.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,605 shares of the company’s stock after acquiring an additional 3,000 shares during the quarter. SG Americas Securities LLC’s holdings in Genelux were worth $135,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. California State Teachers Retirement System purchased a new stake in Genelux in the second quarter worth $30,000. Amalgamated Bank increased its position in Genelux by 250.8% in the third quarter. Amalgamated Bank now owns 1,077 shares of the company’s stock worth $26,000 after buying an additional 770 shares during the last quarter. Tower Research Capital LLC TRC purchased a new position in shares of Genelux in the first quarter valued at $32,000. Legal & General Group Plc grew its position in shares of Genelux by 535.2% in the third quarter. Legal & General Group Plc now owns 1,696 shares of the company’s stock valued at $41,000 after purchasing an additional 1,429 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Genelux by 2,105.0% in the second quarter. JPMorgan Chase & Co. now owns 2,205 shares of the company’s stock valued at $72,000 after purchasing an additional 2,105 shares in the last quarter. 37.33% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Benchmark reissued a “speculative buy” rating and set a $30.00 price objective on shares of Genelux in a research note on Wednesday, April 3rd. HC Wainwright dropped their price objective on Genelux from $35.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd.

Genelux Price Performance

NASDAQ:GNLX opened at $3.62 on Thursday. Genelux Co. has a 52-week low of $3.42 and a 52-week high of $40.98. The stock has a fifty day moving average of $6.36 and a 200 day moving average of $11.70.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.